These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30828586)

  • 1. Bridging from Intramuscular to Limb Perfusion Delivery of rAAV: Optimization in a Non-human Primate Study.
    Gruntman AM; Gernoux G; Tang Q; Ye GJ; Knop DR; Wang G; Benson J; Coleman KE; Keeler AM; Mueller C; Chicoine LG; Chulay JD; Flotte TR
    Mol Ther Methods Clin Dev; 2019 Jun; 13():233-242. PubMed ID: 30828586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Regional Intravenous (RI) Versus Intramuscular (IM) Delivery of rAAV1 and rAAV8 to Nonhuman Primate Skeletal Muscle.
    Toromanoff A; Chérel Y; Guilbaud M; Penaud-Budloo M; Snyder RO; Haskins ME; Deschamps JY; Guigand L; Podevin G; Arruda VR; High KA; Stedman HH; Rolling F; Anegon I; Moullier P; Le Guiner C
    Mol Ther; 2008 Jul; 16(7):1291-1299. PubMed ID: 28178483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results.
    Flotte TR; Trapnell BC; Humphries M; Carey B; Calcedo R; Rouhani F; Campbell-Thompson M; Yachnis AT; Sandhaus RA; McElvaney NG; Mueller C; Messina LM; Wilson JM; Brantly M; Knop DR; Ye GJ; Chulay JD
    Hum Gene Ther; 2011 Oct; 22(10):1239-47. PubMed ID: 21609134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical characterization of a recombinant adeno-associated virus type 1-pseudotyped vector demonstrates dose-dependent injection site inflammation and dissemination of vector genomes to distant sites.
    Flotte TR; Conlon TJ; Poirier A; Campbell-Thompson M; Byrne BJ
    Hum Gene Ther; 2007 Mar; 18(3):245-56. PubMed ID: 17376008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.
    Brantly ML; Chulay JD; Wang L; Mueller C; Humphries M; Spencer LT; Rouhani F; Conlon TJ; Calcedo R; Betts MR; Spencer C; Byrne BJ; Wilson JM; Flotte TR
    Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16363-8. PubMed ID: 19706466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors.
    Lu Y; Song S
    Proc Natl Acad Sci U S A; 2009 Oct; 106(40):17158-62. PubMed ID: 19805176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle.
    Toromanoff A; Chérel Y; Guilbaud M; Penaud-Budloo M; Snyder RO; Haskins ME; Deschamps JY; Guigand L; Podevin G; Arruda VR; High KA; Stedman HH; Rolling F; Anegon I; Moullier P; Le Guiner C
    Mol Ther; 2008 Jul; 16(7):1291-9. PubMed ID: 18461055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector.
    Lu Y; Choi YK; Campbell-Thompson M; Li C; Tang Q; Crawford JM; Flotte TR; Song S
    J Gene Med; 2006 Jun; 8(6):730-5. PubMed ID: 16518879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.
    Mueller C; Chulay JD; Trapnell BC; Humphries M; Carey B; Sandhaus RA; McElvaney NG; Messina L; Tang Q; Rouhani FN; Campbell-Thompson M; Fu AD; Yachnis A; Knop DR; Ye GJ; Brantly M; Calcedo R; Somanathan S; Richman LP; Vonderheide RH; Hulme MA; Brusko TM; Wilson JM; Flotte TR
    J Clin Invest; 2013 Dec; 123(12):5310-8. PubMed ID: 24231351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults.
    Brantly ML; Spencer LT; Humphries M; Conlon TJ; Spencer CT; Poirier A; Garlington W; Baker D; Song S; Berns KI; Muzyczka N; Snyder RO; Byrne BJ; Flotte TR
    Hum Gene Ther; 2006 Dec; 17(12):1177-86. PubMed ID: 17115945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longevity of rAAV vector and plasmid DNA in blood after intramuscular injection in nonhuman primates: implications for gene doping.
    Ni W; Le Guiner C; Gernoux G; Penaud-Budloo M; Moullier P; Snyder RO
    Gene Ther; 2011 Jul; 18(7):709-18. PubMed ID: 21390073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects.
    Song S; Scott-Jorgensen M; Wang J; Poirier A; Crawford J; Campbell-Thompson M; Flotte TR
    Mol Ther; 2002 Sep; 6(3):329-35. PubMed ID: 12231168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes.
    Kang W; Wang L; Harrell H; Liu J; Thomas DL; Mayfield TL; Scotti MM; Ye GJ; Veres G; Knop DR
    Gene Ther; 2009 Feb; 16(2):229-39. PubMed ID: 18923452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of gene therapy for α-1 antitrypsin deficiency.
    Loring HS; Flotte TR
    Expert Opin Biol Ther; 2015 Mar; 15(3):329-36. PubMed ID: 25363251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans.
    Gernoux G; Gruntman AM; Blackwood M; Zieger M; Flotte TR; Mueller C
    Mol Ther; 2020 Mar; 28(3):747-757. PubMed ID: 31982038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of hFIX expression mediated by rAAV8 and rAAV1 administrated intramuscularly.
    Cao Z; Zheng P; Lin Y
    Cytotherapy; 2007; 9(6):593-9. PubMed ID: 17882724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice.
    Nakai H; Fuess S; Storm TA; Muramatsu S; Nara Y; Kay MA
    J Virol; 2005 Jan; 79(1):214-24. PubMed ID: 15596817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method.
    Chulay JD; Ye GJ; Thomas DL; Knop DR; Benson JM; Hutt JA; Wang G; Humphries M; Flotte TR
    Hum Gene Ther; 2011 Feb; 22(2):155-65. PubMed ID: 20812844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type I Viral Vectors.
    Conlon TJ; Mah CS; Pacak CA; Rucker Henninger MB; Erger KE; Jorgensen ML; Lee CC; Tarantal AF; Byrne BJ
    Hum Gene Ther Clin Dev; 2016 Dec; 27(4):152-159. PubMed ID: 27855487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The in vivo and in vitro effects on neovascularization of VEGF gene transfer with a new pseudotyped rAAV1 vector].
    Yan H; Wu XB; Guo YH; Zhang P; Chen L; Dong XY; Wang GS; Gao W
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Jan; 35(1):69-73. PubMed ID: 17386170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.